Study of Lipid Profile and Apolipoprotein in Patients Diagnosed with the Coronary Heart Disease
Authors/Creators
- 1. Assistant Professor, Department of Biochemistry, Shri Ramkrishna Institute of Medical Sciences and Sanaka Hospitals, Durgapur, West Bengal, India
Description
The cause of CHD is atherosclerosis. Atherosclerosis is a chronic inflammatory response of the arterial wall initiated by an injury to the endothelium by activation of various factors for which apolipoproteins have been implicated. Moreover, lesion progression is sustained by interaction between modified lipoproteins (e.g. oxidized low density lipoprotein), lipid laden macrophage (foam cells), T-lymphocytes and the normal cellular constituents of the arterial wall. Atherosclerosis is also characterized by thickening of the arterial wall, which protrudes into and obstructs the vascular lumen. Hence based on above findings the present study was planned for Assessment of Apolipoprotein and Lipid Profile in Patients Diagnosed with the Coronary Heart Disease.
The present study was planned in Department of Biochemistry, Shri Ramkrishna institute of medical sciences and Sanaka Hospitals, Durgapur, West Bengal, India for 1 year . The 20 cases were enrolled in Group A as cases of coronary heart disease and 20 cases were enrolled in Group B as control cases for comparative study. Estimation of serum Apo A-I and Apo B were done by Turbidimetric Immunoassay, serum cholesterol by cholesterol oxidase- peroxidase (CHOD-PAP) enzymatic colorimetric end point method, HDL cholesterol and LDL cholesterol by direct enzymatic method and serum triglycerides by glycerol phosphate oxidase peroxidase (GPO-PAP) enzymatic end point method.
The data generated from the present study concludes that the levels of apo A1 and apo B are strongly related to CHD in addition to the conventional lipid profile. Our findings support the consideration of the measurement of serum Lipo-A as a screening tool for the risk of ischemic heart disease. Therefore, this study suggests the need for routine measurement of apo A1 and apo B in the diagnosis of CHD and thus helps in early detection of myocardial damage which warrants timely intervention leading to lowered morbidity and mortality.
Abstract (English)
The cause of CHD is atherosclerosis. Atherosclerosis is a chronic inflammatory response of the arterial wall initiated by an injury to the endothelium by activation of various factors for which apolipoproteins have been implicated. Moreover, lesion progression is sustained by interaction between modified lipoproteins (e.g. oxidized low density lipoprotein), lipid laden macrophage (foam cells), T-lymphocytes and the normal cellular constituents of the arterial wall. Atherosclerosis is also characterized by thickening of the arterial wall, which protrudes into and obstructs the vascular lumen. Hence based on above findings the present study was planned for Assessment of Apolipoprotein and Lipid Profile in Patients Diagnosed with the Coronary Heart Disease.
The present study was planned in Department of Biochemistry, Shri Ramkrishna institute of medical sciences and Sanaka Hospitals, Durgapur, West Bengal, India for 1 year . The 20 cases were enrolled in Group A as cases of coronary heart disease and 20 cases were enrolled in Group B as control cases for comparative study. Estimation of serum Apo A-I and Apo B were done by Turbidimetric Immunoassay, serum cholesterol by cholesterol oxidase- peroxidase (CHOD-PAP) enzymatic colorimetric end point method, HDL cholesterol and LDL cholesterol by direct enzymatic method and serum triglycerides by glycerol phosphate oxidase peroxidase (GPO-PAP) enzymatic end point method.
The data generated from the present study concludes that the levels of apo A1 and apo B are strongly related to CHD in addition to the conventional lipid profile. Our findings support the consideration of the measurement of serum Lipo-A as a screening tool for the risk of ischemic heart disease. Therefore, this study suggests the need for routine measurement of apo A1 and apo B in the diagnosis of CHD and thus helps in early detection of myocardial damage which warrants timely intervention leading to lowered morbidity and mortality.
Files
IJTPR,Vol12,Issue11,Article7.pdf
Files
(317.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:fd235d9412e20a1dbe2def358fbc5399
|
317.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-11-10
Software
References
- 1. Coronary Artery Disease (CAD). 12 March 2013. Archived from the original on 2 March 2015. Retrieved 23 February 2015. 2. Rezende PC, Scudeler TL, da Costa LM, Hueb W. Conservative strategy for treatment of stable coronary artery disease. World Journal of Clinical Cases. February 2015; 3(2): 163–70. 3. Centers for Disease Control Prevention (CDC). Prevalence of coronary heart disease- United States, 2006-2010. MMWR. Morbidity and Mortality Weekly Report. October 2011; 60(40): 1377–81. 4. Kontos MC, Diercks DB, Kirk JD. Emergency department and office-based evaluation of patients with chest pain. Mayo Clinic Proceedings. March 2010; 85(3): 284–99. 5. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism. October 2001; 44(10): 2331–7. 6. McCann S.J.H. The precocity-longevity hypothesis: earlier peaks in career achievement predict shorter lives. Pers Soc Psychol Bull. November 2001; 27(11): 1429–39. 7. Rhodewalt, Smith. Current issues in Type A behaviour, coronary proneness, and coronary heart disease. In Snyder, C.R.; Forsyth, D.R. (eds.). Handbook of social and clinical psychology: the health perspective. New York: Pergamon. 1991;197–220. 8. Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000prime Reports. 2015;7:08. 9. Aziz S, Ramsdale DR. Chronic total occlusions- a stiff challenge requiring a major breakthrough: is there light at the end of the tunnel? Heart. June 2005; 91 Suppl 3 (suppl_3): iii; 428. 10. 10. American Society of Echocardiography. Five Things Physicians and Patients Should Question. Choosing Wisely: An Initiative of the ABIM Foundation. Archived from the original on 26 February 2013. Retrieved 27 February 2013. 11. Coronary Angiography. National Heart, Blood, and Lung Institute. Retrieved 10 December 2017. 12. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. The Cochrane Database of Systematic Reviews. January 2011; (1): CD001561. 13. Population nutrient intake goals for preventing diet-related chronic diseases. WHO. Archived from the original on 29 December 2015. Retrieved 26 October 2015. 14. Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and doseresponse meta-analysis of prospective cohort studies. BMJ. July 2014; 349: 4490. 15. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuously graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256(20): 2823-8. 16. Gupta R, Gupta VP, Sarna M, Bhatnagar AS, Thanvi J, Sharma V, et al. Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch. Indian Heart J. 2002; 54(1):59-66. 17. Enas EA, Jacob S. Coronary artery disease in Indians in the USA. In: Coronary Artery Disease in Indians: A Global Perspective. Sethik, (Ed.), Cardiological Society of India; Mumbai. 1998:32-43. 18. Walldius G, Jungner I: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipidlowering therapy — a review of the evidence. J Intern Med. 2006; 259:493– 519. 19. Gupta R, Kaul V. Prakash H, Saran M, Gupta VP. Lipid abnormalities in coronary heart disease: a populationbased case-control studies. Indian Heart J. 2001; 52(3): 332-6 20. Enas A, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol. 1992;70(9): 945-9. 21. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asian's: a review. J Clin Epidemiol. 1989;42(7):597- 609. 22. Naito HK. Apolipoproteins: Biochemistry, metabolism and clinical significance developed by lipid and lipoprotien division. Clin Chem. 1987;33:1051-52. 23. Stein EA. Lipids. In: Text Book of Clinical. Chemistry. Ed Teitz NB. London, WB. Saunders Co. 1986; 829- 900. 24. Bae JH, Schwemmer M, Lee IK, et al. Postprandial hypertriglyceridemia induced endothelial dysfunction in healthy subjects is independent of lipid oxidation. Int J Cardiol. 2003; 87: 259-67. 25. Genest JG Jr. Dyslipidemia and coronary artery disease. Can J Cardiol. 2000;16 Suppl A:3A-4. 26. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: An analysis from the interheart Study. J Am Coll Cardiol. 2009;53:244- 53. 27. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The residual risk reduction initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:1K-34. 28. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: A review. J Clin Epidemiol. 1989; 42:597-609. 29. Batool D. R., Jamal D. K., Sheroze D. M. W., Bhatti D. I. A., Jaffar D. N., Haider, D. G., & Faridi D. M. A. Clinical features of colorectal carcinoma at the Jinnah Postgraduate Medical Centre, Karachi, Pakistan: a cross-sectional study. Journal of Medical Research and Health Sciences. 2022; 5(9): 2203–2209.